-
1 Comment
Zhejiang Tianyu Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 25.3% below its 200 day moving average.
From a valuation standpoint, the stock is 29.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.8.
Zhejiang Tianyu Pharmaceutical Co., Ltd's total revenue rose by 11.2% to $672M since the same quarter in the previous year.
Its net income has increased by 3.5% to $197M since the same quarter in the previous year.
Finally, its free cash flow fell by 97.1% to $2M since the same quarter in the previous year.
Based on the above factors, Zhejiang Tianyu Pharmaceutical Co., Ltd gets an overall score of 3/5.
| Exchange | SHE |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| CurrencyCode | CNY |
| ISIN | CNE1000034X1 |
| Target Price | 22 |
|---|---|
| Market Cap | 8B |
| PE Ratio | 74.69 |
| Dividend Yield | 0.2% |
| Beta | 0.66 |
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, and anti-asthmatic series. It provides fine chemicals and CDMO services. Zhejiang Tianyu Pharmaceutical Co., Ltd. was founded in 1993 and is based in Taizhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300702.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
